Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors.
Scott E Lazerwith,Gina Bahador,Eda Canales,Guofeng Cheng,Lee Chong,Michael O Clarke,Edward Doerffler,Eugene J Eisenberg,Jaclyn Hayes,Bing Lu,Qi Liu,Mike Matles,Michael Mertzman,Michael L Mitchell,Philip Morganelli,Bernard P Murray,Margaret Robinson,Robert G Strickley,Megan Tessler,Neeraj Tirunagari,Jianhong Wang,Yujin Wang,Jennifer R Zhang,Xubin Zheng,Weidong Zhong,William J Watkins
DOI: https://doi.org/10.1021/ml200163b
2011-01-01
ACS Medicinal Chemistry Letters
Abstract:A novel series of HCV replication inhibitors based on a pyrido[3,2-d]pyrimidine core were optimized for pharmacokinetics (PK) in rats. Several associations between physicochemical properties and PK were identified and exploited to guide the design of compounds. In addition, a simple new metric that may aid in the prediction of bioavailability for compounds with higher polar surface area is described (3*HBD-cLogP).